Extracellular-Vesicle Manufacturing Standards Checklist

Use this checklist to examine whether a supplier can document the material source, controlled processing, isolation method, particle characterisation, safety testing, storage conditions and batch trail for an extracellular-vesicle product. It is a document-assessment tool, not proof of clinical suitability, legal classification, regulatory compliance or product approval.

How to use this extracellular-vesicle manufacturing checklist

This is a buyer's document checklist for extracellular-vesicle, or EV, products. Work through it against a specific batch, rather than against a brochure or a general company presentation. A useful response includes the document requested, its version or issue date, the batch identifier to which it applies, and the responsible organisation. A statement that a process is "tested" or "quality controlled" does not itself establish what was measured, when it was measured, or whether the result relates to the vial under review.

The International Society for Extracellular Vesicles, through its MISEV guidance, emphasises transparent reporting of source material, separation, characterisation and functional work. That reporting framework is useful here because EV preparations are heterogeneous. A particle count alone cannot establish identity, purity, composition or reproducibility.

1. Open a batch assessment record. Record product name, batch or lot number, fill date, expiry or retest date, format, stated storage condition and the document set received. Why it matters: without a batch anchor, a certificate or method description may concern another production run. Source: MISEV guidance from the International Society for Extracellular Vesicles stresses reporting sufficient for interpretation and reproducibility.
2. Separate evidence from assertion. Mark each claim as supported by a batch record, a controlled procedure, a third-party certificate, or an undated marketing statement. Why it matters: these forms of evidence answer different questions and should not be treated as interchangeable. Source: the International Organization for Standardization describes documented quality-management processes, while MISEV guidance addresses EV reporting.

Screenshot decision rule

Related reading on this publication includes Sourcing and manufacture and Storage and reconstitution on arrival.

Checklist: source material and donor or cell-line provenance

Start with the biological starting material. "Exosome" is often used commercially where the available evidence supports only a broader EV preparation. The source may be conditioned cell-culture medium, a body fluid, or another biological material. These starting points bring different contaminants, traceability needs and interpretation limits. Ask for a description precise enough to distinguish source material from the final preparation.

1. 3. Identify the starting material in exact terms. Check whether the file says conditioned medium, a named biofluid, or another source, and whether it distinguishes EVs from the wider secretome. Why it matters: source material affects likely co-isolates and the meaning of subsequent measurements. Source: MISEV guidance from the International Society for Extracellular Vesicles calls for clear description of EV source and collection.
2. 4. Request provenance and passage history where cultured cells are used. Look for cell identity records, the origin of the cell bank, passage range, culture-medium components and harvest criteria. Why it matters: changes in culture conditions and cellular state can alter material released into conditioned medium. Source: MISEV guidance addresses reporting of cell culture and conditioning details; the International Organization for Standardization's ISO 20387 addresses general requirements for biobanking.
3. 5. Ask how biological materials were qualified before processing. The file should distinguish donor or starting-material qualification from final-product testing. Why it matters: a final assay does not replace traceable controls at the source stage. Source: ISO 20387 provides a framework for competence, impartiality and consistent operation in biobanking.
4. 6. Check whether animal-derived inputs are declared. Where culture supplements or processing aids are used, ask whether they are named and how residual material is considered. Why it matters: unreported inputs can complicate interpretation of composition and purity. Source: MISEV guidance asks investigators to report culture conditions and relevant components.

For a more detailed explanation of this issue, consult Why the cell source matters. This checklist does not determine whether a source is appropriate for a particular clinical use.

Checklist: controlled processing and isolation method

EV isolation is a separation problem, not a single universal manufacturing method. Differential centrifugation, density-based approaches, size-exclusion chromatography, filtration, precipitation and affinity methods can enrich different fractions and carry different co-isolates. A product label that names one technique does not reveal the full workflow. The important question is whether the supplier can describe the sequence of operations and its controls.

1. 7. Obtain the complete separation workflow. Ask for the order of clarification, concentration, filtration, chromatography, centrifugation or other separation stages, including any pooling step. Why it matters: the same final label can describe materially different preparations. Source: MISEV guidance from the International Society for Extracellular Vesicles recommends reporting separation and concentration procedures in sufficient detail.
2. 8. Identify the claimed mechanism of enrichment. Record whether the process separates principally by size, density, affinity or another property. Why it matters: a method's separation principle helps a buyer ask focused questions about likely non-EV material. Source: MISEV guidance discusses the limitations and reporting needs of EV separation approaches.
3. 9. Check controls on critical process parameters. Look for controlled ranges or recorded settings for variables such as filtration cut-off, centrifugation conditions, column use, hold time and processing temperature, where relevant. Why it matters: reproducibility depends on defined and recorded process conditions, not merely a method name. Source: ISO 13485 sets requirements for quality-management systems where an organisation needs to demonstrate consistent provision of medical-device-related processes; it does not certify an EV preparation as suitable for any use.
4. 10. Ask whether the process is closed, partly closed or open. Request a factual description of transfers and exposure points. Why it matters: this identifies where environmental controls and handling records matter most. Source: ISO 14644 provides standards for cleanrooms and associated controlled environments.

A documented method can support reproducibility assessment. It does not, by itself, establish purity, potency, classification or clinical performance.

Checklist: identity, composition and particle characterisation

Characterisation should answer more than "how many particles?". Particle-counting methods can detect particles that are not EVs, and a result may vary with instrument settings, sample preparation and data processing. MISEV guidance recommends characterisation using complementary approaches, with attention to EV-associated features and non-EV co-isolates. The appropriate panel depends on source and process, so this checklist asks for method transparency rather than a universal numerical threshold.

1. 11. Request the method behind every particle concentration result. Check the analytical platform, dilution approach, calibration or controls, reporting unit and whether the result is batch-specific. Why it matters: numbers generated by different methods are not automatically interchangeable. Source: MISEV guidance from the International Society for Extracellular Vesicles discusses the need for orthogonal characterisation and transparent methods.
2. 12. Look for complementary evidence of EV-associated material. Ask which protein, lipid, nucleic-acid, imaging or other approaches were used, and what each was intended to show. Why it matters: no single readout establishes all relevant properties of an EV preparation. Source: MISEV guidance recommends multiple characterisation categories.
3. 13. Ask how non-EV components were assessed. The report should state whether likely contaminants or co-isolates were considered, rather than presenting enrichment as complete purification. Why it matters: separation methods can co-isolate proteins, lipoproteins, aggregates or other particles depending on the source. Source: MISEV guidance addresses contaminants and the limits of EV isolation terminology.
4. 14. Check whether acceptance criteria are defined before release. Record each criterion, method and result, including any out-of-specification investigation. Why it matters: a result without a pre-defined decision rule gives limited information about release control. Source: ISO 13485 addresses documented procedures and monitoring within a quality-management system.

Do not convert a marker panel into a claim that a product contains only exosomes. In many real-world preparations, "small EV" or "EV-enriched preparation" may be more supportable language.

Checklist: safety-related testing, storage and shipping records

Safety-related release testing, identity testing and environmental controls are separate evidence streams. A sterility result does not establish EV identity, while particle characterisation does not establish microbiological quality. Ask what test was performed, which sample was tested, what method was used and whether the result applies to the filled batch. Where a supplier relies on outsourced testing, the chain between manufacturer, sample and laboratory should still be clear.

1. 15. Obtain the batch safety-testing panel and methods. Check which tests were performed for microbial contamination, endotoxin or other relevant risks, and whether the document names the method and result. Why it matters: broad phrases such as "sterile tested" leave the scope and applicability of the test unclear. Source: the European Pharmacopoeia contains general chapters on microbiological quality and endotoxins; applicability depends on the material and intended regulatory context.
2. 16. Verify sample representativeness. Ask whether the test sample came from the final container, a pooled intermediate or another point in manufacture. Why it matters: test timing changes what a result can support. Source: ISO 13485 requires documented controls over monitoring and measurement processes.
3. 17. Match storage instructions to stability evidence. Request the stated storage range, permitted excursions, freeze-thaw limit, reconstitution instructions where relevant, and the supporting stability protocol. Why it matters: a storage label is not the same as evidence that measured attributes remain within specification through the stated period. Source: the International Council for Harmonisation's stability guideline describes principles for stability testing of drug substances and products, though its direct applicability depends on product status.
4. 18. Check transport-chain records. Ask for dispatch conditions, temperature-monitoring approach, excursion procedure and receipt assessment. Why it matters: a conforming release result cannot describe conditions after dispatch. Source: ISO 9001 sets general principles for documented control of processes and retained information.

See Storage and reconstitution on arrival for an arrival-focused assessment. This publication does not provide instructions for administering, reconstituting or selecting a product for a person.

Checklist: batch traceability, certificates and change control

Traceability is the ability to connect a final container to its source materials, processing history, test results, storage history and distribution record. It is not achieved by a lot number alone. A strong document pack lets a buyer identify what changed, which batch was affected and whether a certificate is contemporaneous with the material received. This is particularly important where a product presentation appears consistent while the source, process or analytical method has changed.

1. 19. Reconcile identifiers across every document. The batch number, product presentation, fill date and expiry or retest information should agree across the certificate, shipping record and label. Why it matters: mismatched identifiers break the evidence chain. Source: ISO 13485 addresses identification and traceability within applicable quality-management systems.
2. 20. Request a certificate of analysis and the underlying specification. Check that each reported result has a method, unit, acceptance criterion and batch identifier. Why it matters: a certificate summarises release information but may omit raw data, deviations, sampling plans and method validation. Source: MISEV guidance supports transparent reporting of EV characterisation; ISO 13485 addresses control of monitoring and measuring information.
3. 21. Ask for change-control history. Request disclosure of material changes to source, culture conditions, isolation, testing, container closure, storage or transport instructions. Why it matters: comparability cannot be assumed after a meaningful process change. Source: ISO 13485 requires documented procedures for review and control of changes where applicable.
4. 22. Check complaint, deviation and recall traceability. Ask whether the supplier can identify affected batches and recipients if a quality issue is found. Why it matters: corrective action depends on a retrievable distribution trail. Source: ISO 13485 includes requirements relevant to feedback, nonconforming product and traceability processes.

For a practical procurement comparison, use this alongside London regenerative aesthetics standards checklist. A complete document pack is evidence of documentation practice, not an endorsement of a supplier or product.

Limits: what this checklist does not establish

This checklist is limited to assessing manufacturing and document evidence for an EV product. It does not determine whether a product is legally classified in the United Kingdom or elsewhere, whether it requires authorisation, whether a quality system certificate applies to the product in question, or whether a particular intended use is permitted. Classification can depend on presentation, mode of action, route, processing and jurisdiction, and it should be assessed from current official advice.

It also does not establish clinical benefit, safety for an individual, dose, suitability, treatment choice or outcome. Those are patient and clinical questions. Readers considering whether to receive a product should seek appropriate clinical advice; exosomestherapy.co.uk addresses the patient decision separately.

Nor does the checklist turn a named standard into a universal EV manufacturing standard. ISO 9001, ISO 13485, ISO 14644 and ISO 20387 have defined scopes. A certificate to one of them may provide evidence about a management system, environment or biobanking operation, but it does not automatically verify a specific batch's EV identity, purity, safety testing or regulatory position.

Finally, the checklist cannot resolve missing evidence by inference. If a supplier cannot provide a batch-linked method, result, acceptance criterion or traceability record, record the item as unavailable. Do not replace it with a general statement, an image of a logo or a claim based on another batch.